Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262

Llovet, 2016, Hepatocellular carcinoma, Nat Rev Dis Primers, 2, 16018, 10.1038/nrdp.2016.18

McGlynn, 2015, Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability, Clin Liver Dis, 19, 223, 10.1016/j.cld.2015.01.001

2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9

Whiteside, 2016, Emerging opportunities and challenges in cancer immunotherapy, Clin Cancer Res, 22, 1845, 10.1158/1078-0432.CCR-16-0049

Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8

Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665

Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001

Prieto, 2015, Immunological landscape and immunotherapy of hepatocellular carcinoma, Nat Rev Gastroenterol Hepatol, 12, 681, 10.1038/nrgastro.2015.173

Shi, 2011, PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients, Int J Cancer, 128, 887, 10.1002/ijc.25397

Flecken, 2014, Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma, Hepatology, 59, 1415, 10.1002/hep.26731

Breous, 2011, Potential of immunotherapy for hepatocellular carcinoma, J Hepatol, 54, 830, 10.1016/j.jhep.2010.10.013

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

1990, EuroQol: a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase 3 randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7

Bruix, 2012, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial, J Hepatol, 57, 821, 10.1016/j.jhep.2012.06.014

Cheng, 2012, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial, Eur J Cancer, 48, 1452, 10.1016/j.ejca.2011.12.006

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627

Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087

Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 385, 1856, 10.1056/NEJMoa1602252

Sangro, 2013, A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, J Hepatol, 59, 81, 10.1016/j.jhep.2013.02.022